New strategies for targeting the therapy of NSCLC: The role of ERCC1 and TS

P. Ceppi; M. Papotti; G. Scagliotti

doi:10.2478/v10039-010-0017-4

New strategies for targeting the therapy of NSCLC: The role of ERCC1 and TS

P. Ceppi^*, M. Papotti, G. Scagliotti

^*Corresponding author for this work

University of Turin

Research output: Contribution to journal › Journal article › Research › peer-review

Abstract

The evaluation of gene and protein expression profiles is a promising strategy to drive the therapeutical decision-making in non-small cell lung cancer (NSCLC). Among the several candidate genes that have been proposed, many retrospective studies have indicated excision repair cross-complementing 1 (ERCC1), an endonuclease responsible for the repair of DNA damages, as a reliable biomarker of tumor sensitivity to platinum-based agents. Moreover, the recent evidences showing the clinical efficacy of next-generation multitargeted antifolate drugs, in NSCLC, have highlighted the role of the determination of thymidylate synthase (TS) expression levels. Here is presented a brief overview of the literature regarding these two genes that are currently under prospective investigation as predictive markers of treatment efficacy in NSCLC.

Original language	English
Journal	Advances in Medical Sciences
Volume	55
Issue number	1
Pages (from-to)	22-25
ISSN	1896-1126
DOIs	https://doi.org/10.2478/v10039-010-0017-4
Publication status	Published - 1. Jun 2010
Externally published	Yes

Keywords

excision repair cross-complementing 1
non-small cell lung cancer
Thymidylate synthase

Documents & Links

10.2478/v10039-010-0017-4

Cite this

@article{97ec7247f15e44f08fe478a6128db9d9,

title = "New strategies for targeting the therapy of NSCLC: The role of ERCC1 and TS",

abstract = "The evaluation of gene and protein expression profiles is a promising strategy to drive the therapeutical decision-making in non-small cell lung cancer (NSCLC). Among the several candidate genes that have been proposed, many retrospective studies have indicated excision repair cross-complementing 1 (ERCC1), an endonuclease responsible for the repair of DNA damages, as a reliable biomarker of tumor sensitivity to platinum-based agents. Moreover, the recent evidences showing the clinical efficacy of next-generation multitargeted antifolate drugs, in NSCLC, have highlighted the role of the determination of thymidylate synthase (TS) expression levels. Here is presented a brief overview of the literature regarding these two genes that are currently under prospective investigation as predictive markers of treatment efficacy in NSCLC.",

keywords = "excision repair cross-complementing 1, non-small cell lung cancer, Thymidylate synthase",

author = "P. Ceppi and M. Papotti and G. Scagliotti",

year = "2010",

month = jun,

day = "1",

doi = "10.2478/v10039-010-0017-4",

language = "English",

volume = "55",

pages = "22--25",

journal = "Advances in Medical Sciences",

issn = "1896-1126",

publisher = "Medical University of Bialystok",

number = "1",

}

TY - JOUR

T1 - New strategies for targeting the therapy of NSCLC

T2 - The role of ERCC1 and TS

AU - Ceppi, P.

AU - Papotti, M.

AU - Scagliotti, G.

PY - 2010/6/1

Y1 - 2010/6/1

N2 - The evaluation of gene and protein expression profiles is a promising strategy to drive the therapeutical decision-making in non-small cell lung cancer (NSCLC). Among the several candidate genes that have been proposed, many retrospective studies have indicated excision repair cross-complementing 1 (ERCC1), an endonuclease responsible for the repair of DNA damages, as a reliable biomarker of tumor sensitivity to platinum-based agents. Moreover, the recent evidences showing the clinical efficacy of next-generation multitargeted antifolate drugs, in NSCLC, have highlighted the role of the determination of thymidylate synthase (TS) expression levels. Here is presented a brief overview of the literature regarding these two genes that are currently under prospective investigation as predictive markers of treatment efficacy in NSCLC.

AB - The evaluation of gene and protein expression profiles is a promising strategy to drive the therapeutical decision-making in non-small cell lung cancer (NSCLC). Among the several candidate genes that have been proposed, many retrospective studies have indicated excision repair cross-complementing 1 (ERCC1), an endonuclease responsible for the repair of DNA damages, as a reliable biomarker of tumor sensitivity to platinum-based agents. Moreover, the recent evidences showing the clinical efficacy of next-generation multitargeted antifolate drugs, in NSCLC, have highlighted the role of the determination of thymidylate synthase (TS) expression levels. Here is presented a brief overview of the literature regarding these two genes that are currently under prospective investigation as predictive markers of treatment efficacy in NSCLC.

KW - excision repair cross-complementing 1

KW - non-small cell lung cancer

KW - Thymidylate synthase

U2 - 10.2478/v10039-010-0017-4

DO - 10.2478/v10039-010-0017-4

M3 - Journal article

C2 - 20494871

AN - SCOPUS:77954530710

SN - 1896-1126

VL - 55

SP - 22

EP - 25

JO - Advances in Medical Sciences

JF - Advances in Medical Sciences

IS - 1

ER -

New strategies for targeting the therapy of NSCLC: The role of ERCC1 and TS

Abstract

Keywords

Documents & Links

Fingerprint

Cite this